Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism

American Journal of Medicine

Volumn 110, Issue 2, 2001, Pages 91-96

  Haim, Nissim ^a,b   Lanir, Naomi ^a   Hoffman, Ron ^a   Haim, Amir ^a   Tsalik, Medi ^a   Brenner, Benjamin ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; MUTANT PROTEIN; THROMBOPLASTIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; RISK FACTOR; THROMBOEMBOLISM; THROMBOPLASTIN TIME;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 0035253810     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00691-4     Document Type: Article

References (20)

1. Venous thromboembolism and cancer: A two-way clinical association
2. Pathophysiology of the thrombophilic state in the cancer patient
3. The thrombophilic state induced by therapeutic agents in the cancer patient
4. Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
5. Anticoagulant protein C pathway defective in majority of thrombophilic patients
6. Mutation in blood coagulation factor V associated with resistance to activated protein C
7. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
8. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
9. Antiphospholipid antibody syndrome: New insights on thrombogenic mechanisms
10. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives
11. Development of resistance to activated protein C during pregnancy
12. 506 mutation in unselected oncology patients
13. Activated-protein C resistance in cancer patients
14. Hypercoagulable state in patients with advanced gastrointestinal cancer: Evidence for an acquired resistance to activated protein C
15. Reporting results of cancer treatment
16. Laboratory diagnosis of APC resistance: A critical evaluation of the test and the development of diagnostic criteria
17. Modified test for activated protein C resistance
18. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
19. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden
20. Antiphospholipid antibodies and syndromes